Different doses of methylprednisolone in the treatment of myasthenia gravis

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800018623

Enrollment

Unknown

Registered

2018-09-30

Start date

2018-10-15

Completion date

Unknown

Last updated

2018-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myasthenia gravis

Interventions

Group 1:High dose hormone

Group 2:5 days hormone

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-60 years male or female; 2. According to Ossermen modified classification, the diagnosis of myasthenia gravis type II; 3. Sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Cardiopulmonary and liver and kidney functions are severely impaired, malignant tumors, various hemorrhagic diseases, acute infectious diseases, pregnant women, psychiatric patients; 2. Use other drugs to treat patients; 3. Taking part in other clinical research patients.

Design outcomes

Primary

Measure	Time frame
remission rate;	—

Secondary

Measure	Time frame
Adverse reactions;Frequency of adverse events;The quality of life evaluation;Duration and severity of exacerbation;	—

Countries

China

Contacts

Public ContactGuoyan Qi

The First Hospital of Shijiazhuang

qiguoyan1106@sina.com+86 17603119295

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026